A Resource for Healthcare and Social Services Professionals
Words Matter
Words to use and avoid when talking about addiction.
Initiation of Brixadi® Extended-Release Injectable Buprenorphine for Opioid Use Disorder
Guidance for starting a patient on Brixadi® extended-release injectable buprenorphine for the treatment of opioid use disorder. This is not meant to replace clinical decision-making.
Visit webpageInitiation of Naltrexone for Alcohol Use Disorder
Guidance for starting a patient on naltrexone for the treatment of alcohol use disorder. This is not meant to replace clinical decision-making.
Download fileInitiation of Naltrexone for Opioid Use Disorder
Guidance for starting a patient on long-acting injectable naltrexone for the treatment of opioid use disorder. This is not meant to replace clinical decision-making.
Download fileInitiation of Sublocade® Extended-Release Injectable Buprenorphine for Opioid Use Disorder
Guidance for starting a patient on Sublocade® extended-release injectable buprenorphine for the treatment of opioid use disorder. This is not meant to replace clinical decision-making.
Visit webpageInitiation of Transmucosal Buprenorphine for Opioid Use Disorder
Guidance for starting a patient on transmucosal buprenorphine for the treatment of opioid use disorder. This is not meant to replace clinical decision-making.
Download filePain Management While on Buprenorphine for Opioid Use Disorder
Guidance for managing acute and chronic pain in patients already on buprenorphine for opioid use disorder. This is not meant to replace clinical decision-making.
Download filePain Management While on Naltrexone
Guidance for managing acute (anticipated or unanticipated) or chronic pain in patients already on naltrexone. This is not meant to replace clinical decision-making.
Download fileBrixadi® Dosing Conversion Tables
Suggested Brixadi® corresponding dosage for patients transitioning from daily sublingual buprenorphine or monthly Sublocade® treatment to monthly or weekly Brixadi® treatment. Tables show the suggested corresponding Brixadi® dose based on current sublingual buprenorphine or Sublocade® dosage.
Visit webpageChecklist Prior to Buprenorphine-Naloxone Initiation
Please reference the 2021 Boston Medical Center OBAT Clinical Guidelines, pages 27-28.
Visit webpageChecklist Prior to Monthly Buprenorphine Injection
Please reference the 2021 Boston Medical Center OBAT Clinical Guidelines, pages 45-46.
Visit webpageChecklist Prior to Naltrexone Initiation
Please reference the 2021 Boston Medical Center OBAT Clinical Guidelines, pages 55-56.
Visit webpageCOWS Scale Opioid Withdrawal Record Induction Form
Download fileDSM-5 Checklist of Diagnostic Criteria: Opioid Use Disorder
Download fileExtended-Release Injectable Buprenorphine Formulation Selection Tool
This tool outlines considerations for each FDA-approved extended-release injectable buprenorphine formulation.
Visit webpageNovel Naloxone Distribution Strategies
This document outlines potential strategies to increase patient access to nasal naloxone by serving as a guide for administrators, healthcare providers, and non-medical providers attempting to create reimbursable streams for naloxone.
Download filePatient Medication Guide for Injectable Naltrexone (Vivitrol)
Visit webpagePerioperative Management
This document gives management guidelines for patients maintained on buprenorphine who are scheduled for surgery or other procedures.
Download fileTransfer Guidelines for Methadone to Buprenorphine or Buprenorphine to Naltrexone Transition
Please reference the 2021 Boston Medical Center OBAT Clinical Guidelines, pages 33-36.
Visit webpage Consent for Release of Information (CFR 42)
Consent for Treatment with Disulfiram
Consent for Treatment with Extended-Release Injectable Buprenorphine Formulations
Visit Grayken TTA's Extended-Release Buprenorphine resources page to access consent forms in English, Haitian-Creole, Portuguese, and Spanish for treatment with Brixadi® or Sublocade® extended-release injectable buprenorphine formulations.
Visit webpage Consent for Treatment with Naltrexone
Sample OBAT Treatment Agreement
Transmucosal Buprenorphine Consent Form
Buprenorphine Patient Education Sheet
This informational sheet for patients covers what buprenorphine is, how it works, how it is typically administered, possible side effects, and other important things to know.
Download fileBuprenorphine Self Start: Setting Yourself Up for a Successful Initiation - Patient Guide
This patient guide reviews the basics for patients starting transmucosal buprenorphine in the home or community setting. It may be used to educate patients on the initiation process and what they may experience when starting buprenorphine.
Download fileCustomizable Patient Guide to Starting Buprenorphine
This customizable patient handout helps providers create a tailored plan for patients starting transmucosal buprenorphine treatment, ensuring it aligns with the patient's unique needs and goals. The handout is intended to be filled out by the provider alongside the patient as they review each step of the patient’s buprenorphine initiation plan together and additional medications that may be used during the initiation of buprenorphine and management of acute opioid withdrawal.
Download fileExtended-Release Injectable Buprenorphine Patient Education Sheets
Visit Grayken TTA's Extended-Release Buprenorphine resources page to access patient education sheets for Brixadi® and Sublocade® extended-release injectable buprenorphine.
Visit webpageBuprenorphine Initiation Note
Download fileInitial Screening Note Template
Download fileOBAT Nursing Follow-up Note
Example of an OBAT nursing follow-up note used for ongoing assessment of patients engaged in treatment. This template includes documentation of medications for addiction treatment including injectable buprenorphine. This sample visit documentation is meant to serve as a guide.
Download fileOBAT Nursing Intake Note
Example of an OBAT nursing intake note used for comprehensive assessment of new patients. This sample visit documentation is meant to serve as a guide.
Download file
Grayken Center for Addiction TTA is a program of Boston Medical Center (BMC), a 514-bed academic medical center located in Boston's historic South End and the largest safety-net hospital in New England.
The content on this site and the content presented by Grayken Center for Addiction TTA is intended solely to inform and educate healthcare and social service professionals, and shall not be used for medical advice and is not a substitute for the advice or treatment of a qualified medical professional. The hospital, the program, and the contributors are not acting as health care providers or professional consultants on behalf of any specific patient and disclaim establishing a provider-patient relationship with any specific patient.